Direct oral anticoagulants (DOAC) and left atrial appendage closure (LAAC) have similar stroke and death outcomes in patients with atrial fibrillation (AF), but younger patients who undergo LAAC have lower bleeding events, a secondary analysis of the CHAMPION-AF trial shows.